About Vermillion (NASDAQ:VRML)
Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRML
CUSIPN/A
Phone512-519-0400
Debt
Debt-to-Equity Ratio0.44%
Current Ratio2.42%
Quick Ratio2.38%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.12 million
Price / Sales31.88
Cash FlowN/A
Price / CashN/A
Book Value$0.06 per share
Price / Book23.67
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-10,490,000.00
Net Margins-336.33%
Return on Equity-206.13%
Return on Assets-117.38%
Miscellaneous
Employees40
Outstanding Shares70,040,000
Vermillion (NASDAQ:VRML) Frequently Asked Questions
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) posted its quarterly earnings results on Tuesday, March, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.80 million for the quarter. Vermillion had a negative return on equity of 206.13% and a negative net margin of 336.33%. View Vermillion's Earnings History.
What price target have analysts set for VRML?
1 brokerages have issued 12-month target prices for Vermillion's shares. Their forecasts range from $2.25 to $2.25. On average, they anticipate Vermillion's stock price to reach $2.25 in the next twelve months. View Analyst Ratings for Vermillion.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), AspenBio Pharma (RIOT), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Genenews (GNWSF), ARCA biopharma (ABIO), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- Ms. Valerie Barber Palmieri, Chief Exec. Officer, Pres and Director (Age 57)
- Mr. Fred Ferrara, Chief Operating Officer (Age 50)
- Mr. Robert Harry Beechey, Chief Financial Officer
- Dr. Marra Francis M.D., Chief Medical Officer
- Mr. Patrick Carpenter, Gen. Mang. of ASPiRA LABS
Has Vermillion been receiving favorable news coverage?
News headlines about VRML stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vermillion earned a news impact score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Vermillion?
Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
One share of VRML stock can currently be purchased for approximately $1.42.
How big of a company is Vermillion?
Vermillion has a market capitalization of $86.15 million and generates $3.12 million in revenue each year. Vermillion employs 40 workers across the globe.
How can I contact Vermillion?
Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]
MarketBeat Community Rating for Vermillion (VRML)
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe VRML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vermillion (NASDAQ:VRML) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Vermillion in the last 12 months. Their average twelve-month price target is $2.25, suggesting that the stock has a possible upside of 58.45%. The high price target for VRML is $2.25 and the low price target for VRML is $2.25. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.25 | $2.25 | $2.25 | $1.75 |
| Price Target Upside: | 58.45% upside | 53.12% upside | 53.12% upside | 32.58% upside |
Vermillion (NASDAQ:VRML) Consensus Price Target History
Vermillion (NASDAQ:VRML) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/2/2017 | Canaccord Genuity | Boost Price Target | Buy | $1.75 -> $2.25 | N/A |  |
(Data available from 4/23/2016 forward)
Vermillion (NASDAQ:VRML) Earnings History and Estimates Chart
Vermillion (NASDAQ VRML) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/13/2018 | Q4 2017 | | ($0.05) | | $0.80 million | View | N/A | |
| 11/8/2017 | Q3 2017 | ($0.04) | ($0.06) | | $0.70 million | View | N/A | |
| 8/9/2017 | Q2 2017 | ($0.04) | ($0.04) | | $0.90 million | View | Listen | |
| 5/18/2017 | Q1 2017 | ($0.04) | ($0.05) | | $0.73 million | View | N/A | |
| 3/29/2017 | Q4 2016 | | ($0.05) | | $0.81 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.06) | ($0.07) | | $0.62 million | View | N/A | |
| 8/10/2016 | Q216 | ($0.09) | ($0.07) | | $0.71 million | View | Listen | |
| 5/16/2016 | Q116 | ($0.09) | ($0.09) | | $0.51 million | View | Listen | |
| 3/24/2016 | Q415 | | ($0.10) | $1.20 million | $0.36 million | View | Listen | |
| 11/12/2015 | Q315 | ($0.10) | ($0.10) | $0.57 million | $0.33 million | View | Listen | |
| 8/13/2015 | Q215 | ($0.08) | ($0.11) | $1.50 million | $535.00 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.10) | ($0.10) | $0.81 million | $0.95 million | View | Listen | |
| 3/25/2015 | Q414 | ($0.08) | ($0.11) | $1.59 million | $1.57 million | View | Listen | |
| 11/13/2014 | Q3 2014 | | ($0.16) | | $0.32 million | View | N/A | |
| 8/14/2014 | Q2 2014 | | ($0.15) | | $0.32 million | View | N/A | |
| 5/15/2014 | Q1 2014 | | ($0.11) | | $0.31 million | View | N/A | |
| 3/6/2014 | Q4 2013 | | ($0.07) | | $1.59 million | View | N/A | |
| 11/14/2013 | Q3 | | ($0.10) | $319.00 million | $330.00 million | View | Listen | |
| 8/14/2013 | Q2 2013 | | ($0.11) | $0.3210 million | $0.2320 million | View | Listen | |
| 5/15/2013 | Q1 2013 | ($0.15) | ($0.17) | $0.30 million | $0.3280 million | View | Listen | |
| 2/20/2013 | Q4 2012 | ($0.10) | ($0.09) | | | View | N/A | |
| 11/12/2012 | Q312 | ($0.21) | ($0.13) | | | View | N/A | |
| 8/14/2012 | Q2 2012 | | ($0.13) | | | View | N/A | |
| 5/15/2012 | Q1 2012 | | ($0.15) | | | View | N/A | |
| 3/27/2012 | Q4 2011 | ($0.42) | ($0.21) | | | View | N/A | |
| 11/9/2011 | Q3 2011 | ($0.49) | ($0.31) | | | View | N/A | |
| 8/4/2011 | Q2 2011 | ($0.45) | ($0.39) | | | View | N/A | |
| 5/10/2011 | Q1 2011 | ($0.44) | ($0.37) | | | View | N/A | |
| 2/10/2011 | Q4 2010 | ($0.39) | ($0.37) | | | View | N/A | |
| 11/11/2010 | Q3 2010 | ($0.36) | ($0.35) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Vermillion (NASDAQ:VRML) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vermillion (NASDAQ VRML) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.67%
Institutional Ownership Percentage: 29.69%
Vermillion (NASDAQ VRML) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Jack W Schuler | Major Shareholder | Buy | 2,838,090 | $1.00 | $2,838,090.00 | | |
| 11/15/2017 | Valerie Barber Palmieri | CEO | Buy | 685 | $1.46 | $1,000.10 | 61,963 | |
| 10/16/2017 | Valerie Barber Palmieri | Insider | Buy | 694 | $1.44 | $999.36 | 61,278 | |
| 9/15/2017 | Valerie Barber Palmieri | Insider | Buy | 719 | $1.39 | $999.41 | 60,584 | |
| 8/23/2017 | Valerie Barber Palmieri | Insider | Buy | 768 | $1.30 | $998.40 | 59,865 | |
| 5/17/2017 | Valerie Barber Palmieri | Insider | Buy | 555 | $1.80 | $999.00 | 59,097 | |
| 2/17/2017 | Larry N Feinberg | Insider | Buy | 617,731 | $1.40 | $864,823.40 | | |
| 2/13/2017 | Eric Schoen | SVP | Buy | 3,347 | $1.40 | $4,685.80 | 29,872 | |
| 2/13/2017 | Jack W Schuler | Major Shareholder | Buy | 974,081 | $1.40 | $1,363,713.40 | 6,673,029 | |
| 2/13/2017 | Valerie Barber Palmieri | CEO | Buy | 10,042 | $1.40 | $14,058.80 | 58,542 | |
| 2/13/2017 | Veronica Gh Jordan | Director | Buy | 6,695 | $1.40 | $9,373.00 | 70,315 | |
| 1/28/2016 | Jack W Schuler | Major Shareholder | Buy | 1,493 | $1.60 | $2,388.80 | 6,673,029 | |
| 1/25/2016 | Jack W Schuler | Major Shareholder | Buy | 3,700 | $1.57 | $5,809.00 | 6,673,029 | |
| 1/21/2016 | Jack W Schuler | Major Shareholder | Buy | 30,700 | $1.46 | $44,822.00 | 6,673,029 | |
| 1/19/2016 | Jack W Schuler | Major Shareholder | Buy | 57,749 | $1.45 | $83,736.05 | 6,673,029 | |
| 1/15/2016 | Jack W Schuler | Major Shareholder | Buy | 8,400 | $1.56 | $13,104.00 | 6,673,029 | |
| 7/14/2015 | Larry N Feinberg | Insider | Buy | 512,043 | $1.96 | $1,003,604.28 | | |
| 12/23/2014 | Jack W Schuler | Major Shareholder | Buy | 1,288,339 | $1.44 | $1,855,208.16 | | |
| 12/23/2014 | Larry N Feinberg | Insider | Buy | 972,222 | $1.44 | $1,399,999.68 | | |
| 12/19/2014 | Peter S Roddy | Director | Buy | 16,502 | $1.44 | $23,762.88 | | |
| 11/21/2014 | Valerie Barber Palmieri | COO | Buy | 3,500 | $1.51 | $5,285.00 | | |
| 11/20/2014 | James T Lafrance | Insider | Buy | 27,907 | $1.44 | $40,186.08 | | |
| 11/20/2014 | Valerie Barber Palmieri | COO | Buy | 30,000 | $1.44 | $43,200.00 | | |
| 11/19/2014 | James T Lafrance | Insider | Buy | 41,615 | $1.43 | $59,509.45 | | |
| 11/18/2014 | Eric Schoen | CAO | Buy | 5,000 | $1.42 | $7,100.00 | | |
| 11/20/2013 | William B Creech | VP | Buy | 2,000 | $2.33 | $4,660.00 | | |
| 6/11/2013 | William B Creech | VP | Buy | 10,000 | $3.18 | $31,800.00 | | |
(Data available from 1/1/2013 forward)
Vermillion (NASDAQ VRML) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Contrasting Vermillion (VRML) & BG Medicine (BGMD)
www.americanbankingnews.com - April 23 at 5:22 PM |
 | Friday 4/20 Insider Buying Report: VRML, HYB
www.nasdaq.com - April 20 at 4:23 PM |
| Vermillion, Inc. (VRML) Major Shareholder Purchases $2,838,090.00 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
 | Vermillion Energy to buy Spartan Energy for about C$1.4 billion
www.reuters.com - April 16 at 9:33 AM |
 | Vermillion (VRML) Prices $15 Million Public Offerings of Common Stock and Preferred Stock
www.streetinsider.com - April 13 at 4:20 PM |
| After-Hours Stock Movers 04/12: (DPW) (AVGO) (NWL) Higher; (VRML) (MBI) (SEAS) Lower (more...)
www.streetinsider.com - April 13 at 10:05 AM |
| BRIEF-Vermillion Announces Pricing Of $15 Mln Concurrent Public Offerings Of Stock
www.reuters.com - April 13 at 10:05 AM |
 | Vermillion, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
globenewswire.com - April 13 at 10:05 AM |
 | Vermillion prices equity offerings; shares down 25%
seekingalpha.com - April 13 at 10:05 AM |
 | Vermillion Inc (NASDAQ:VRML): Immense Growth Potential?
finance.yahoo.com - April 4 at 5:13 PM |
| Did Vermillion Inc’s (NASDAQ:VRML) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - March 23 at 4:14 PM |
| Edited Transcript of VRML earnings conference call or presentation 13-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 9:34 AM |
| Vermillion Reports Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - March 13 at 6:09 PM |
| Vermillion to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 7 at 5:05 PM |
| Short Interest in Vermillion, Inc. (VRML) Declines By 31.3%
www.americanbankingnews.com - March 4 at 1:20 AM |
| Vermillion to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, March 13
finance.yahoo.com - February 28 at 9:34 AM |
| Vermillion to Present at the 2018 BTIG Healthcare Conference
finance.yahoo.com - February 23 at 9:34 AM |
| What Is Vermillion Inc’s (NASDAQ:VRML) Share Price Doing?
finance.yahoo.com - February 20 at 9:13 AM |
| Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
finance.yahoo.com - February 13 at 9:01 AM |
| Vermillion (VRML) Says it was Granted of Two Ovarian Cancer Diagnostic Patents
www.streetinsider.com - February 6 at 9:00 AM |
 | Will Austin lose biopharma HQ to Connecticut? It depends on who you ask
www.bizjournals.com - January 23 at 8:28 AM |
| Vermillion (VRML) Announces Agreement with BlueCross BlueShield of Illinois for OVA1
www.streetinsider.com - January 19 at 12:04 PM |
| Vermillion Announces Agreement with BlueCross BlueShield of Illinois
finance.yahoo.com - January 18 at 11:36 AM |
| Vermillion, Inc. :VRML-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:18 AM |
| Are Vermillion Inc’s (NASDAQ:VRML) Interest Costs Too High?
finance.yahoo.com - December 26 at 8:31 PM |
| Austin cancer-fighting company shuffles a pair of C-suite financial execs
www.bizjournals.com - December 22 at 10:44 AM |
| Vermillion Appoints Bob Beechey to Newly Created CFO Post
finance.yahoo.com - December 19 at 10:34 AM |
| Analyzing InVitae (NVTA) & Vermillion (VRML)
www.americanbankingnews.com - December 17 at 5:34 PM |
| Short Interest in Vermillion, Inc. (VRML) Increases By 80.4%
www.americanbankingnews.com - December 15 at 2:04 AM |
| Analyzing InVitae (NVTA) and Vermillion (VRML)
www.americanbankingnews.com - December 12 at 11:38 PM |
| Reviewing Vermillion (VRML) and InVitae (NVTA)
www.americanbankingnews.com - December 8 at 9:08 PM |
| Critical Survey: Vermillion (VRML) and Digiliti Money Group (DGLT)
www.americanbankingnews.com - December 6 at 7:46 PM |
| Vermillion, Inc. (VRML) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - November 25 at 6:46 AM |
| Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 5:28 PM |
| ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1
finance.yahoo.com - November 20 at 12:07 PM |
| Vermillion Announces Publication of Foundational Health Economics Study
finance.yahoo.com - November 18 at 10:08 AM |
| Vermillion, Inc. (VRML) Issues Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 9 at 2:52 PM |
| Vermillion Reports Third Quarter 2017 Results
www.bizjournals.com - November 9 at 9:38 AM |
| Edited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:38 AM |
| Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
finance.yahoo.com - November 7 at 1:11 PM |
| Vermillion, Inc. (VRML) Price Target Raised to $2.25 at Canaccord Genuity
www.americanbankingnews.com - November 2 at 7:42 PM |
| ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
finance.yahoo.com - November 1 at 10:32 AM |
| ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield
finance.yahoo.com - October 31 at 11:57 AM |
| Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th
finance.yahoo.com - October 28 at 8:23 AM |
| ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®
finance.yahoo.com - October 28 at 8:23 AM |
| ETFs with exposure to Vermillion, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 2:40 PM |
| ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
finance.yahoo.com - October 3 at 2:40 PM |
| Vermillion, Inc. (VRML) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 30 at 3:50 AM |
| Is It Too Late To Buy Vermillion Inc (VRML)?
finance.yahoo.com - September 23 at 10:49 AM |
| ETFs with exposure to Vermillion, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 8:30 PM |
Vermillion (NASDAQ:VRML) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vermillion (NASDAQ:VRML) Income Statement, Balance Sheet and Cash Flow Statement
Vermillion (NASDAQ VRML) Stock Chart for Monday, April, 23, 2018
Loading chart…
